[1] |
PATTERSON T F, THOMPSON G R 3rd, DENNING D W, et al. Practice guidelines for the diagnosis and management of aspergillosis:2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 63(4):e1-e60.
|
[2] |
PAPPAS P G, KAUFFMAN C A, ANDES D R, et al. Clinical practice guideline for the management of candidiasis:2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016, 62(4):e1-e50.
|
[3] |
JIN H, WANG T, FALCIONE B A, et al. Trough concentration of voriconazole and its relationship with efficacy and safety:a systematic review and meta-analysis[J]. J Antimicrob Chemother, 2016, 71(7):1772-1785.
|
[4] |
HOENIGL M, DUETTMANN W, RAGGAM R B, et al. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies[J]. Antimicrob Agents Chemother, 2013, 57(7):3262-3267.
DOI
PMID
|
[5] |
MORIYAMA B, OBENG A O, BARBARINO J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy[J]. Clin Pharmacol Ther, 2017, 102(1):45-51.
DOI
PMID
|
[6] |
林志强, 张清泉, 陈婷婷. 伏立康唑的治疗药物监测:国内外相关指南概览[J]. 药物不良反应杂志, 2020, 22(7):409-415.
DOI
|
[7] |
WANG T, XIE J, WANG Y, et al. Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections[J]. Pharmacotherapy, 2015, 35 (9):797-804.
|
[8] |
伍三兰, 蔡华丹, 赵妮, 等. 伏立康唑致肝毒性临床特点[J]. 医药导报, 2018, 37(3):387-390.
DOI
|
[9] |
王晓梅, 张林. 84例伏立康唑不良反应分析[J]. 药物不良反应与不良事件, 2017, 36(12):1432-1436.
|
[10] |
CHEN K, ZHANG X, KE X, et al. Individualized medication of voriconazole:a practice guideline of the Division of Therapeutic Drug Monitoring,Chinese Pharmacological Society[J]. Ther Drug Monit, 2018, 40(6):663-674.
|
[11] |
叶健, 卓广超, 等. HPLC法测定人血浆中伏立康唑的浓度[J]. 中国药房, 2021, 32(20):2525-2529.
|
[12] |
马霖, 孙加琳, 李恩泽, 等. LC-MS-MS法同时测定人血浆中伏立康唑和替加环素的浓度[J]. 中国临床药理学杂志, 2019, 35(24):3237-3240.
|
[13] |
LI X, LI W, LI M, et al. Correlation between enzyme multiplied immunoassay technique and high-performance liquid chromatography in the quantification of voriconazole in a paediatricpopulation[J]. Scand J Clin Lab Invest, 2021, 81(2):121-126.
|
[14] |
陈君, 黄春新, 王敏. 超高效液相色谱法测定人血清中伏立康唑血药浓度与临床应用[J]. 海南医学, 2021, 32(2):173-176.
|
[15] |
Clinical and Laboratory Standards Institute. Liquid chromatography-mass spectrometry methods[S]. C62-A,CLSI, 2014.
|
[16] |
Clinical and Laboratory Standards Institute. Mass spectrometry in the clinical laboratory:general principles and guidance[S]. C50-A,CLSI, 2007.
|
[17] |
沈敏, 杨晓东, 王琳, 等. 血清总同型半胱氨酸候选参考测量程序(液相色谱串联质谱法)的建立及性能评估[J]. 检验医学, 2018, 33(11):1018-1025.
DOI
|
[18] |
EI-KHOURY J M, BUNCH D R, REINEKS E, et al. A simple and fast liquid chromatography-tandem mass spectrometry method for measurement of underivatized L-arginine,symmetric dimethylarginine,and asymmetric dimethylarginine and establishment of the reference ranges[J]. Anal Bioanal Chem, 2012, 402(2):771-779.
DOI
PMID
|
[19] |
International Organization for Standardization. Guide to the expression of uncertainty in measurement[S]. 1995.
|
[20] |
张元元, 刘维, 周从亚, 等. LC-MS/MS同时测定人血浆中伏立康唑和泊沙康唑的浓度[J]. 中国临床药理学杂志, 2020, 36(12):1697-1700.
|
[21] |
钟皎, 郝琨, 裴泽军. UPLC-MS/MS法测定人血浆中伏立康唑的浓度及其临床应用[J]. 中国药房, 2016, 27(29):4064-4066.
|
[22] |
刘洋, 邱婷婷, 张弨. HPLC-MS/MS法测定人血浆中伏立康唑浓度[J]. 中国临床药理学杂志, 2018, 34(10):1222-1225.
|